Albumin binding is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-20. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
The overall fold of the KaiA monomer is that of a four-helix bundle, which forms a dimer in the known structure. KaiA functions as a homodimer. Each monomer is composed of three functional domains: the N-terminal amplitude-amplifier domain, the central period-adjuster domain and the C-terminal clock-oscillator domain. The N-terminal domain of KaiA, from cyanobacteria, acts as a pseudo-receiver domain, but lacks the conserved aspartyl residue required for phosphotransfer in response regulators. The C-terminal domain is responsible for dimer formation, binding to KaiC, enhancing KaiC phosphorylation and generating the circadian oscillations. The KaiA protein from Anabaena sp. (strain PCC 7120) lacks the N-terminal CheY-like domain. KaiB adopts an alpha-beta meander motif and is found to be a dimer or a tetramer. KaiC belongs to a larger family of proteins; it performs autophosphorylation and acts as its own transcriptional repressor. It binds ATP.
Tranexamic acid might alleviate neuroinflammation in some experimental settings. Tranexamic acid can be used in case of postpartum hemorrhage; it can decrease the risk of death due to bleeding by one third according to the WHO. Tentative evidence supports the use of tranexamic acid in hemoptysis. In hereditary angioedema In hereditary hemorrhagic telangiectasia: tranexamic acid has been shown to reduce the frequency of epistaxis in patients with severe and frequent nosebleed episodes from hereditary hemorrhagic telangiectasia. In melasma: tranexamic acid is sometimes used in skin whitening as a topical agent, injected into a lesion, or taken by mouth, both alone and as an adjunct to laser therapy; as of 2017 its safety seemed reasonable but its efficacy for this purpose was uncertain because there had been no large scale randomized controlled studies nor long term follow-up studies. It is allowed as a quasi-drug for skin whitening in Japan. In hyphema: tranexamic acid is effective in reducing the risk of secondary hemorrhage outcomes in people with traumatic hyphema. In liver resection: tranexamic acid did not reduce bleeding or transfusions but did increase complications.
To completely block the uptake of iodine-131 by the purposeful addition of perchlorate ions to a populace's water supply, aiming at dosages of 0.5 mg/kg-day, or a water concentration of 17 ppm, would therefore be grossly inadequate at truly reducing radioiodine uptake. Perchlorate ion concentrations in a region's water supply would need to be much higher, at least 7.15 mg/kg of body weight per day, or a water concentration of 250 ppm, assuming people drink 2 liters of water per day, to be truly beneficial to the population at preventing bioaccumulation when exposed to a radioiodine environment, independent of the availability of iodate or iodide drugs. The continual distribution of perchlorate tablets or the addition of perchlorate to the water supply would need to continue for no less than 80–90 days, beginning immediately after the initial release of radioiodine was detected. After 80–90 days passed, released radioactive iodine-131 would have decayed to less than 0.1% of its initial quantity, at which time the danger from biouptake of iodine-131 is essentially over. In the event of a radioiodine release, the ingestion of prophylaxis potassium iodide, if available, or even iodate, would rightly take precedence over perchlorate administration, and would be the first line of defense in protecting the population from a radioiodine release.
Ertugliflozin, sold under the brand name Steglatro, is a medication used for the treatment of type 2 diabetes. The most common side effects include fungal infections of the vagina and other infections of the female reproductive system. Ertugliflozin is a sodium/glucose cotransporter 2 (SGLT2) inhibitor and is in the class of drugs known as gliflozins. In the United States, it was approved by the Food and Drug Administration for use as a monotherapy and as a fixed dose combination with either sitagliptin or with metformin. In the European Union, it was approved in March 2018, for use as a monotherapy or combination therapy. A study published in September 2020, found that ertugliflozin to be essentially non-inferior to placebo with respect to cardiovascular events. A combination with metformin is sold under the brand name Segluromet and a combination with sitagliptin is sold under the brand name Steglujan.
The most common liver injuries from weight loss and bodybuilding supplements involve hepatocellular damage with resulting jaundice, and the most common supplement ingredients attributed to these injuries are green tea catechins, anabolic steroids, and the herbal extract, aegeline. Weight loss supplements have also had adverse psychiatric effects. Some dietary supplements may also have adverse interactions with prescription medications that may enhance side effects or decrease therapeutic effects of medications.
Sources: en.wikipedia.org
==== Dentistry ==== Dentists and endodontists use EDTA solutions to remove inorganic debris (smear layer) and lubricate the root canals in endodontics. This procedure helps prepare root canals for obturation. Furthermore, EDTA solutions with the addition of a surfactant loosen up calcifications inside a root canal and allow instrumentation (canal shaping) and facilitate apical advancement of a file in a tight or calcified root canal towards the apex.
=== Evolution === For at least 1.2 billion years, eukaryotes—a classification of life forms that includes single-cell species, fungi, plants, and animals, but not bacteria, characterized by cells with a membrane-bound nucleus—have been able to synthesize 7-dehydrocholesterol. When this molecule is exposed to UVB light from the sun it absorbs the energy in the process of being converted to vitamin D. The function was to prevent DNA damage, the converted molecule being an end product without vitamin function. Present day, phytoplankton in the ocean photosynthesize vitamin D without any calcium management function, as do some species of algae, lichen, fungi, and plants. Only circa 500 million years ago, when animals began to leave the oceans for land, did the UV-converted molecule take on a hormone function as a promoter of calcium regulation. This function required the development of a nuclear vitamin D receptor (VDR) that binds the biologically active vitamin D metabolite 1α,25-dihydroxyvitamin (D3), plasma transport proteins, and vitamin D metabolizing CYP450 enzymes regulated by calciotropic hormones. The triumvirate of receptor protein, transport and metabolizing enzymes are found only in vertebrates. The initial vitamin function evolved for control of metabolic genes supporting innate and adaptive immunity. Only later did the VDR system start to act as an important regulator of calcium supply for a calcified skeleton in land-based vertebrates.
== History == Potassium permanganate was first made in the 1600s and came into common medical use at least as early as the 1800s. During World War I Canadian soldiers were given potassium permanganate (to be applied mixed with an ointment) in an effort to prevent sexually transmitted infections (resulting mostly in violet stained genitals.) Some have attempted to bring about an abortion by putting it in the vagina, though this is not effective. Other historical uses have included as an effort to wash out the stomach in those with strychnine or picrotoxin poisoning.
=== Shock, tilt, and vibration monitoring === Shock indicators, tilt indicators, and vibration monitors can be attached to products, packages, pallets, or shipping containers. They show or record when handling conditions exceed a selected limit. Digital data loggers can record the magnitude, direction, duration, and timing of shocks and vibrations. The collected information may support product inspection, carrier evaluation, damage investigation, and laboratory package testing. These systems are used with medical equipment, calibrated instruments, electronics, artworks, industrial components, and other sensitive goods.
Sources: en.wikipedia.org
The combination bolus is appropriate for high carb high fat meals such as pizza, pasta with heavy cream sauce, and chocolate cake. A super bolus is a method of increasing the spike of the standard bolus. Since the action of the bolus insulin in the blood stream will extend for several hours, the basal insulin could be stopped or reduced during this time. This facilitates the "borrowing" of the basal insulin and including it into the bolus spike to deliver the same total insulin with faster action than can be achieved with spike and basal rate together. The super bolus is useful for certain foods (like sugary breakfast cereals) which cause a large post-prandial peak of blood sugar. It attacks the blood sugar peak with the fastest delivery of insulin that can be practically achieved by pumping.
== Season 3 (2017) == Eight bakers competed in a six-episode baking tournament. One person got eliminated every week until the final three compete for $25,000. Judges for this season are Carla Hall, Zac Young, and Lorraine Pascale.
=== Leukemia === Leukemia, a cancer of the blood or bone marrow, is characterized by an abnormal increase of immature white blood cells. The risk of childhood leukemia is increased, as demonstrated in a Chinese case–control study, and the risk increases with length of treatment.
=== Proteasomal ligases === While Ubp6 and UCH37 can remodel the ubiquitin code on a substrate by removing Ubiquitins, Ubiquitin ligases can also associate with the proteasome and attach ubiquitins. For the 26S, this includes Hul5 in yeast (or UBE3C in humans) and UBE3A/E6AP in humans. Hul5 was first identified in yeast as a 26S associated ligase along with Ubp6 and they were proposed to remodel ubiquitin chains at the proteasome. Biochemical studies show that Hul5 can attach additional ubiquitins onto a ubiquitinated substrate effectively acting as an Ubiquitin ligase. Hul5 has been proposed to bind Rpn2 in yeast, however this interaction has not been shown structurally. Further work needs to be done to understand how Hul5 works and what substrates are processed by Hul5. UBE3A/E6AP binds the C-terminus of Rpn10 in mammals. NMR has shown that a previously described disordered region of Rpn10 becomes order upon binding E6AP forming a tight interaction in the low nanomolar range.
mole (mol) A unit (symbol: mol) used to measure the amount of a substance in terms of the absolute number of particles or entities composing the substance. By definition, one mole of any substance contains exactly the Avogadro number (i.e. 6.022×1023) of particles or entities.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.